Malignant Ovarian Neoplasm

Back to Diseases List

Associated Genetic Biomarkers

Overview

NCI Definition: A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas. [1]

Biomarker-Directed Therapies

View Therapies for Malignant Ovarian Neoplasm

Of the biomarker-directed therapies for malignant ovarian neoplasm, 4 are FDA-approved in at least one setting and 3 have NCCN guidelines in at least one setting [3].

Niraparib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation, Myriad myChoice HRD Positive

Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)

Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation, Myriad myChoice HRD Positive	Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)
	Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens.

Olaparib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation

Clinical Setting(s): Maintenance therapy (FDA, NCCN), Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)

Note: Indicated for patients with advanced ovarian cancer (1) with BRCA1/2 deleterious germline mutations who have been treated with three or more prior lines of chemotherapy, and (2) for maintenance treatment with BRCA1/2 deleterious germline or somatic mutations with complete or partial response to first-line chemotherapy.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation	Clinical Setting(s): Maintenance therapy (FDA, NCCN), Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)
	Note: Indicated for patients with advanced ovarian cancer (1) with BRCA1/2 deleterious germline mutations who have been treated with three or more prior lines of chemotherapy, and (2) for maintenance treatment with BRCA1/2 deleterious germline or somatic mutations with complete or partial response to first-line chemotherapy.

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation

Clinical Setting(s): Fourth line of therapy (NICE), Maintenance therapy (SMC), Relapse (BNF)

Note: Neither SMC nor NICE restrict BRCA1/2 alterations to germline mutations.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation	Clinical Setting(s): Fourth line of therapy (NICE), Maintenance therapy (SMC), Relapse (BNF)
	Note: Neither SMC nor NICE restrict BRCA1/2 alterations to germline mutations.

Rucaparib +

Bevacizumab + Olaparib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation, Homologous Recombination Deficiency Positive

Clinical Setting(s): Maintenance therapy (FDA)

Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation, Homologous Recombination Deficiency Positive	Clinical Setting(s): Maintenance therapy (FDA)
	Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy.

Clinical Trials

View Clinical Trials for Malignant Ovarian Neoplasm

Significant Genes in Malignant Ovarian Neoplasm

BRCA1 +

BRCA2 +

ERBB2 +

NTRK1 +

NTRK2 +

NTRK3 +

Disease Details

Synonyms

Malignant Tumor of the Ovary, Ovarian Cancer, Malignant Neoplasm of the Ovary, Cancer of the Ovary, Ovary cancer (NOS), Malignant Ovarian Tumor

Parent(s)

Ovarian Neoplasm

Children

Ovarian Wilms Tumor, Ovarian Sarcoma, Krukenberg Tumor, Malignant Ovarian Cyst, Malignant Ovarian Neoplasm, NOS, Malignant Ovarian Germ Cell Tumor, Malignant Ovarian Epithelial Tumor, Ovarian Lymphoma, Ovarian Choriocarcinoma, and Ovarian Malignant Mesothelioma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

Overview

Biomarker-Directed Therapies

Clinical Trials

Significant Genes in Malignant Ovarian Neoplasm

Disease Details

References

About

Molecular Medicine

Content Types